Mammary Carcinoma: Insights from BRCA1 mutations
Genetic Signatures in Canine Mammary Tumors: insights from BRCA1 mutations
Genetic Signatures in Canine Mammary Tumors: insights from BRCA1 mutations
Enter below for your chance to win:
Maggie, a friendly and rambunctious 12 year old, spayed female pug, was diagnosed with malignant oral melanoma in March 2022 by her primary care veterinarian. The mass was located on her upper left dental arcade. Her veterinarian surgically debulked approximately 80% of the mass. Unfortunately, Maggie experienced rapid local recurrence within a month of the surgery, involving the maxilla, and the adjacent mandibular lymph node.
FOR IMMEDIATE RELEASE
Precision Medicine Tools Offer Veterinarians New Hope for Understanding Deadly Dog
Cancer
A 12 year old, neutered male Golden Retriever, underwent a dental prophylaxis procedure performed by his primary care veterinarian in June of 2021. At that time, no suspicious lesions or growths were noted. In October 2021, his family discovered a marble-sized growth in his mouth along the gum line of his left maxilla. The mass was visible from the outside of his mouth, and seemed to cause him irritation. At the time, it was bloody (perhaps from self trauma/stick chewing). Antibiotics were prescribed, but the dog quickly developed worsening clinic signs (nasal discharge, swelling, lethargy).
Canine cancer is a heartbreaking diagnosis that affects millions of beloved pets worldwide. In fact, it’s one of the biggest unmet needs in veterinary medicine. As advancements in our field continue to evolve, FidoCure emerges as a groundbreaking solution, offering a revolutionary approach to treating canine cancer. By harnessing the power of genomic testing, FidoCure provides targeted therapies that are transforming the landscape of canine cancer care.
FOR IMMEDIATE RELEASE
DISCLAIMER: All patients are enrolled in FidoCure® by a veterinarian with a valid veterinarian-client-patient relationship (VCPR). We use best efforts to inform the veterinarian on available targeted therapy options for patients. FidoCure® does not prescribe therapy. The targeted therapies that veterinarians may prescribe and order from compounding pharmacies, after receiving genetic test results from FidoCure®, may constitute extra-label uses of those drugs. FidoCure® makes no claims that every patient will have genetic test results that lead to targeted therapy options. FidoCure® makes no claims or guarantees about the effectiveness of the diagnostic and targeted therapy selected by the veterinarian for an individual patient. Like most cancer care approaches, the services provided by FidoCure® are not a guarantee of a cure. FidoCure® is not a pharmacy and does not supply drugs directly. By ordering any medication via one of our pharmacy partners, you agree that the pharmacy, not FidoCure®, is solely responsible and liable for any and all issues relating to the preparation, dispensation and fulfillment of the medication. The lifetime offer is subject to the commercially reasonable availability of any medication(s) and/or active pharmaceutical ingredient(s) necessary for the selected therapy.
© Copyright 2018-2022 OHC, All rights reserved